Laekna's (HKG:2105) loss narrowed to 254.3 million yuan in 2024 from 368.8 million yuan in 2023, according to a Monday filing with the Hong Kong bourse.
Loss per share at the drug company narrowed to 0.71 yuan from 1.68 yuan in the previous year.
The company did not recognize revenue for the year.
Other income increased to 38.2 million yuan from 16.7 million yuan in 2023.